

Menopause Support Market Forecasts to 2034 – Global Analysis By Support Type (Hormonal Therapies, Non-Hormonal Therapies, Dietary Supplements, Lifestyle and Wellness Solutions, and Medical Devices and Digital Therapeutics), Symptom Type, Route of Administration, Dosage Form, End User, Distribution Channel, and By Geography

<https://marketpublishers.com/r/M96E06DC677CEN.html>

Date: March 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: M96E06DC677CEN

Abstracts

According to Statistics MRC, the Global Menopause Support Market is accounted for \$18.3 billion in 2026 and is expected to reach \$32.0 billion by 2034 growing at a CAGR of 7.2% during the forecast period. Menopause support products encompass pharmaceutical treatments, dietary supplements, and therapeutic delivery systems designed to alleviate symptoms associated with perimenopause and menopause, including hot flashes, mood disturbances, and vaginal atrophy. The market addresses the health needs of the growing aging female population through diverse administration routes and dosage formats. Increasing awareness about menopause management and declining stigma around discussing this life stage are driving product innovation and expanding treatment accessibility across global healthcare systems.

Market Dynamics:

Driver:

Growing aging female population worldwide

Demographic trends show a significant increase in women aged 45-60 globally, creating an expanding addressable market for menopause support solutions. Longer life

expectancy means women spend approximately one-third of their lives in post-menopausal phases, intensifying focus on quality of life during these years. Healthcare systems increasingly recognize menopause as a medical concern requiring comprehensive management rather than an inevitable decline. This demographic shift, combined with rising disposable incomes among mature consumers, generates sustained demand for both pharmaceutical interventions and natural support products addressing symptom management and long-term health preservation.

Restraint:

Social stigma and underreporting of symptoms

Cultural taboos surrounding menopause continue to limit market expansion by discouraging open discussions between women and healthcare providers. Many women endure symptoms silently, unaware of available treatment options or reluctant to seek medical assistance due to embarrassment. This communication gap results in significant underdiagnosis and undertreatment, particularly in regions where aging and female health topics remain sensitive. Healthcare provider training often inadequately addresses menopause management, further contributing to low treatment rates. Breaking these cultural barriers requires sustained educational efforts targeting both consumers and medical professionals across diverse global markets.

Opportunity:

Personalized medicine and digital health integration

Advances in genetic testing and biomarker analysis enable tailored menopause treatment approaches based on individual symptom profiles and health histories. Digital health platforms offering symptom tracking, telehealth consultations, and personalized supplement recommendations create new engagement channels with consumers seeking customized solutions. Wearable devices monitoring sleep patterns, skin temperature, and heart rate variability provide objective data for treatment optimization. This convergence of personalized medicine and digital tools allows companies to develop direct-to-consumer relationships, gather real-world evidence on product efficacy, and create subscription-based models ensuring ongoing customer engagement beyond initial product purchase.

Threat:

Regulatory scrutiny of bioidentical hormones

Increasing regulatory attention on compounded bioidentical hormone therapies threatens a significant market segment favored by consumers seeking "natural" alternatives. Health authorities express concerns about inconsistent potency, lack of standardized dosing, and insufficient safety data for custom-compounded preparations. Manufacturing facilities face intensified inspection requirements, while marketing claims face greater restrictions regarding efficacy comparisons to FDA-approved therapies. Regulatory actions limiting compounded hormone availability could disrupt supply chains and consumer access, potentially driving patients toward conventional pharmaceutical options but creating market uncertainty that impacts investment in product development across the menopause support category.

Covid-19 Impact:

The COVID-19 pandemic disrupted menopause support market dynamics through reduced healthcare access and shifting health priorities. Lockdowns limited routine gynecological visits, delaying new diagnoses and treatment initiations. Telehealth adoption partially offset these disruptions, with virtual consultations for menopause management increasing significantly. Stress and lifestyle changes during pandemic periods exacerbated menopausal symptoms for many women, increasing underlying demand. Supply chain interruptions affected availability of specific products, particularly those requiring cold chain storage. Post-pandemic recovery shows sustained telehealth utilization for menopause care and heightened consumer interest in self-managed wellness solutions.

The Oral segment is expected to be the largest during the forecast period

The Oral segment is expected to account for the largest market share during the forecast period, driven by patient familiarity, ease of administration, and extensive product availability. Tablets and capsules represent conventional dosage forms for hormone therapies, dietary supplements, and herbal remedies addressing menopausal symptoms. Oral formulations offer precise dosing, stable shelf lives, and established manufacturing processes ensuring consistent quality. Consumer preference for discrete, portable, and simple daily routines favors oral administration over more invasive alternatives. Pharmaceutical companies continue developing novel oral delivery technologies improving bioavailability and reducing gastrointestinal side effects.

The Patches segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Patches segment is predicted to witness the highest growth rate, offering consistent hormone delivery through transdermal absorption while avoiding first-pass liver metabolism. Patches provide steady symptom relief without oral medication fluctuations, appealing to women seeking predictable outcomes. Convenience factors include once-weekly application schedules eliminating daily dosing requirements. Growing clinical evidence supporting transdermal estrogen safety regarding cardiovascular and thromboembolic risks compared to oral alternatives drives physician recommendations. Product innovations include smaller, more discreet patches with improved adhesion and reduced skin irritation, expanding patient acceptance and compliance across diverse demographics.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by high healthcare awareness, strong pharmaceutical infrastructure, and progressive attitudes toward women's health. Extensive direct-to-consumer advertising educates women about treatment options, while robust insurance coverage improves treatment accessibility. Major market players maintain headquarters and manufacturing facilities throughout the region, ensuring consistent product availability. Clinical research infrastructure generates extensive safety and efficacy data supporting physician prescribing confidence. Professional medical societies actively publish menopause management guidelines, standardizing treatment approaches and encouraging appropriate therapeutic interventions.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rapidly aging populations, increasing healthcare expenditure, and evolving social attitudes. Countries including Japan, China, and South Korea experience significant demographic shifts with growing cohorts of menopausal women. Rising disposable incomes enable access to premium pharmaceutical and wellness products. Traditional medicine systems incorporating herbal approaches to menopause create natural acceptance of support products. Western pharmaceutical companies increasingly target these markets through strategic partnerships with local distributors. Medical education initiatives improve healthcare provider knowledge, while media discussions gradually reduce cultural stigma surrounding menopause.

Key players in the market

Some of the key players in Menopause Support Market include Bayer AG, Pfizer Inc., AbbVie Inc., Theramex, Astellas Pharma Inc., Eli Lilly and Company, Novartis AG, Amgen Inc., Merck & Co., Inc., GSK plc, Nature's Way Products, LLC, Holland & Barrett Retail Limited, Bonafide Health, LLC, Metagenics, Inc., and Blackmores Limited.

Key Developments:

In February 2026, Bayer presented new real-world evidence from the CHAPTER and REALISE studies at the Menopause Society Annual Meeting, highlighting significant undertreatment in natural menopause and the high use of benzodiazepines for sleep disturbances.

In February 2026, Astellas announced that its non-hormonal drug Veozah (fezolinetant) met its primary endpoint in a Japanese Phase III study, paving the way for regulatory submission and market entry in Japan.

In October 2025, Bonafide released its "State of Menopause" report, revealing that 59% of women aged 40–49 had never heard of perimenopause before experiencing symptoms, driving the company's 2026 strategy toward hormone-free education and clinical-grade supplements.

Support Types Covered:

Hormonal Therapies

Non-Hormonal Therapies

Dietary Supplements

Lifestyle and Wellness Solutions

Medical Devices and Digital Therapeutics

Symptom Types Covered:

Vasomotor Symptoms

Sleep Disorders

Mood and Cognitive Symptoms

Vaginal and Urogenital Symptoms

Bone Health and Osteoporosis

Metabolic and Cardiovascular Concerns

Sexual Health and Libido

Other Symptoms

Route of Administrations Covered:

Oral

Topical and Transdermal

Injectable

Vaginal Delivery Systems

Dosage Forms Covered:

Tablets and Capsules

Softgels

Powders

Liquids and Tonics

Patches

Creams and Gels

Rings and Implants

End Users Covered:

Hospitals

Specialty Clinics

Diagnostic Centers

Homecare Settings

Wellness Centers and Gynecology Clinics

Distribution Channels Covered:

Hospitals and Clinics

Retail Pharmacies and Drug Stores

Online Pharmacies and E-commerce

Specialty Stores

Direct-to-Consumer Platforms

Regions Covered:

North America

United States

Canada

Mexico

Europe

United Kingdom

Germany

France

Italy

Spain

Netherlands

Belgium

Sweden

Switzerland

Poland

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Thailand

Malaysia

Singapore

Vietnam

Rest of Asia Pacific

South America

Brazil

Argentina

Colombia

Chile

Peru

Rest of South America

Rest of the World (RoW)

Middle East

Saudi Arabia

United Arab Emirates

Qatar

Israel

Rest of Middle East

Africa

South Africa

Egypt

Morocco

Rest of Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

- 1.1 Market Snapshot and Key Highlights
- 1.2 Growth Drivers, Challenges, and Opportunities
- 1.3 Competitive Landscape Overview
- 1.4 Strategic Insights and Recommendations

2 RESEARCH FRAMEWORK

- 2.1 Study Objectives and Scope
- 2.2 Stakeholder Analysis
- 2.3 Research Assumptions and Limitations
- 2.4 Research Methodology
 - 2.4.1 Data Collection (Primary and Secondary)
 - 2.4.2 Data Modeling and Estimation Techniques
 - 2.4.3 Data Validation and Triangulation
 - 2.4.4 Analytical and Forecasting Approach

3 MARKET DYNAMICS AND TREND ANALYSIS

- 3.1 Market Definition and Structure
- 3.2 Key Market Drivers
- 3.3 Market Restraints and Challenges
- 3.4 Growth Opportunities and Investment Hotspots
- 3.5 Industry Threats and Risk Assessment
- 3.6 Technology and Innovation Landscape
- 3.7 Emerging and High-Growth Markets
- 3.8 Regulatory and Policy Environment
- 3.9 Impact of COVID-19 and Recovery Outlook

4 COMPETITIVE AND STRATEGIC ASSESSMENT

- 4.1 Porter's Five Forces Analysis
 - 4.1.1 Supplier Bargaining Power
 - 4.1.2 Buyer Bargaining Power
 - 4.1.3 Threat of Substitutes
 - 4.1.4 Threat of New Entrants

- 4.1.5 Competitive Rivalry
- 4.2 Market Share Analysis of Key Players
- 4.3 Product Benchmarking and Performance Comparison

5 GLOBAL MENOPAUSE SUPPORT MARKET, BY SUPPORT TYPE

- 5.1 Hormonal Therapies
 - 5.1.1 Estrogen Therapy
 - 5.1.2 Combined Hormone Therapy
 - 5.1.3 Progesterone Therapy
- 5.2 Non-Hormonal Therapies
 - 5.2.1 Prescription Non-Hormonal Drugs
 - 5.2.2 OTC Non-Hormonal Products
- 5.3 Dietary Supplements
 - 5.3.1 Herbal Supplements
 - 5.3.2 Vitamins and Minerals
 - 5.3.3 Phytoestrogens
 - 5.3.4 Omega Fatty Acids
 - 5.3.5 Probiotics
 - 5.3.6 Combination Supplements
- 5.4 Lifestyle and Wellness Solutions
 - 5.4.1 Fitness and Weight Management
 - 5.4.2 Nutrition Programs
 - 5.4.3 Mental Health and Stress Management
 - 5.4.4 Sleep Support Solutions
- 5.5 Medical Devices and Digital Therapeutics
 - 5.5.1 Pelvic Health Devices
 - 5.5.2 Wearable Health Monitoring
 - 5.5.3 Femtech Platforms
 - 5.5.4 Telehealth and Digital Care Platforms

6 GLOBAL MENOPAUSE SUPPORT MARKET, BY SYMPTOM TYPE

- 6.1 Vasomotor Symptoms
- 6.2 Sleep Disorders
- 6.3 Mood and Cognitive Symptoms
- 6.4 Vaginal and Urogenital Symptoms
- 6.5 Bone Health and Osteoporosis
- 6.6 Metabolic and Cardiovascular Concerns

- 6.7 Sexual Health and Libido
- 6.8 Other Symptoms

7 GLOBAL MENOPAUSE SUPPORT MARKET, BY ROUTE OF ADMINISTRATION

- 7.1 Oral
- 7.2 Topical and Transdermal
- 7.3 Injectable
- 7.4 Vaginal Delivery Systems

8 GLOBAL MENOPAUSE SUPPORT MARKET, BY DOSAGE FORM

- 8.1 Tablets and Capsules
- 8.2 Softgels
- 8.3 Powders
- 8.4 Liquids and Tonics
- 8.5 Patches
- 8.6 Creams and Gels
- 8.7 Rings and Implants

9 GLOBAL MENOPAUSE SUPPORT MARKET, BY END USER

- 9.1 Hospitals
- 9.2 Specialty Clinics
- 9.3 Diagnostic Centers
- 9.4 Homecare Settings
- 9.5 Wellness Centers and Gynecology Clinics

10 GLOBAL MENOPAUSE SUPPORT MARKET, BY DISTRIBUTION CHANNEL

- 10.1 Hospitals and Clinics
- 10.2 Retail Pharmacies and Drug Stores
- 10.3 Online Pharmacies and E-commerce
- 10.4 Specialty Stores
- 10.5 Direct-to-Consumer Platforms

11 GLOBAL MENOPAUSE SUPPORT MARKET, BY GEOGRAPHY

- 11.1 North America

- 11.1.1 United States
- 11.1.2 Canada
- 11.1.3 Mexico
- 11.2 Europe
 - 11.2.1 United Kingdom
 - 11.2.2 Germany
 - 11.2.3 France
 - 11.2.4 Italy
 - 11.2.5 Spain
 - 11.2.6 Netherlands
 - 11.2.7 Belgium
 - 11.2.8 Sweden
 - 11.2.9 Switzerland
 - 11.2.10 Poland
 - 11.2.11 Rest of Europe
- 11.3 Asia Pacific
 - 11.3.1 China
 - 11.3.2 Japan
 - 11.3.3 India
 - 11.3.4 South Korea
 - 11.3.5 Australia
 - 11.3.6 Indonesia
 - 11.3.7 Thailand
 - 11.3.8 Malaysia
 - 11.3.9 Singapore
 - 11.3.10 Vietnam
 - 11.3.11 Rest of Asia Pacific
- 11.4 South America
 - 11.4.1 Brazil
 - 11.4.2 Argentina
 - 11.4.3 Colombia
 - 11.4.4 Chile
 - 11.4.5 Peru
 - 11.4.6 Rest of South America
- 11.5 Rest of the World (RoW)
 - 11.5.1 Middle East
 - 11.5.1.1 Saudi Arabia
 - 11.5.1.2 United Arab Emirates
 - 11.5.1.3 Qatar

- 11.5.1.4 Israel
- 11.5.1.5 Rest of Middle East
- 11.5.2 Africa
 - 11.5.2.1 South Africa
 - 11.5.2.2 Egypt
 - 11.5.2.3 Morocco
 - 11.5.2.4 Rest of Africa

12 STRATEGIC MARKET INTELLIGENCE

- 12.1 Industry Value Network and Supply Chain Assessment
- 12.2 White-Space and Opportunity Mapping
- 12.3 Product Evolution and Market Life Cycle Analysis
- 12.4 Channel, Distributor, and Go-to-Market Assessment

13 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES

- 13.1 Mergers and Acquisitions
- 13.2 Partnerships, Alliances, and Joint Ventures
- 13.3 New Product Launches and Certifications
- 13.4 Capacity Expansion and Investments
- 13.5 Other Strategic Initiatives

14 COMPANY PROFILES

- 14.1 Bayer AG
- 14.2 Pfizer Inc.
- 14.3 AbbVie Inc.
- 14.4 Theramex
- 14.5 Astellas Pharma Inc.
- 14.6 Eli Lilly and Company
- 14.7 Novartis AG
- 14.8 Amgen Inc.
- 14.9 Merck & Co., Inc.
- 14.10 GSK plc
- 14.11 Nature's Way Products, LLC
- 14.12 Holland & Barrett Retail Limited
- 14.13 Bonafide Health, LLC
- 14.14 Metagenics, Inc.

14.15 Blackmores Limited

List Of Tables

LIST OF TABLES

Table 1 Global Menopause Support Market Outlook, By Region (2023–2034) (\$MN)

Table 2 Global Menopause Support Market Outlook, By Support Type (2023–2034) (\$MN)

Table 3 Global Menopause Support Market Outlook, By Hormonal Therapies (2023–2034) (\$MN)

Table 4 Global Menopause Support Market Outlook, By Estrogen Therapy (2023–2034) (\$MN)

Table 5 Global Menopause Support Market Outlook, By Combined Hormone Therapy (2023–2034) (\$MN)

Table 6 Global Menopause Support Market Outlook, By Progesterone Therapy (2023–2034) (\$MN)

Table 7 Global Menopause Support Market Outlook, By Non-Hormonal Therapies (2023–2034) (\$MN)

Table 8 Global Menopause Support Market Outlook, By Prescription Non-Hormonal Drugs (2023–2034) (\$MN)

Table 9 Global Menopause Support Market Outlook, By OTC Non-Hormonal Products (2023–2034) (\$MN)

Table 10 Global Menopause Support Market Outlook, By Dietary Supplements (2023–2034) (\$MN)

Table 11 Global Menopause Support Market Outlook, By Herbal Supplements (2023–2034) (\$MN)

Table 12 Global Menopause Support Market Outlook, By Vitamins and Minerals (2023–2034) (\$MN)

Table 13 Global Menopause Support Market Outlook, By Phytoestrogens (2023–2034) (\$MN)

Table 14 Global Menopause Support Market Outlook, By Omega Fatty Acids (2023–2034) (\$MN)

Table 15 Global Menopause Support Market Outlook, By Probiotics (2023–2034) (\$MN)

Table 16 Global Menopause Support Market Outlook, By Combination Supplements (2023–2034) (\$MN)

Table 17 Global Menopause Support Market Outlook, By Lifestyle and Wellness Solutions (2023–2034) (\$MN)

Table 18 Global Menopause Support Market Outlook, By Fitness and Weight Management (2023–2034) (\$MN)

Table 19 Global Menopause Support Market Outlook, By Nutrition Programs

(2023–2034) (\$MN)

Table 20 Global Menopause Support Market Outlook, By Mental Health and Stress Management (2023–2034) (\$MN)

Table 21 Global Menopause Support Market Outlook, By Sleep Support Solutions (2023–2034) (\$MN)

Table 22 Global Menopause Support Market Outlook, By Medical Devices and Digital Therapeutics (2023–2034) (\$MN)

Table 23 Global Menopause Support Market Outlook, By Pelvic Health Devices (2023–2034) (\$MN)

Table 24 Global Menopause Support Market Outlook, By Wearable Health Monitoring (2023–2034) (\$MN)

Table 25 Global Menopause Support Market Outlook, By Femtech Platforms (2023–2034) (\$MN)

Table 26 Global Menopause Support Market Outlook, By Telehealth and Digital Care Platforms (2023–2034) (\$MN)

Table 27 Global Menopause Support Market Outlook, By Symptom Type (2023–2034) (\$MN)

Table 28 Global Menopause Support Market Outlook, By Vasomotor Symptoms (2023–2034) (\$MN)

Table 29 Global Menopause Support Market Outlook, By Sleep Disorders (2023–2034) (\$MN)

Table 30 Global Menopause Support Market Outlook, By Mood and Cognitive Symptoms (2023–2034) (\$MN)

Table 31 Global Menopause Support Market Outlook, By Vaginal and Urogenital Symptoms (2023–2034) (\$MN)

Table 32 Global Menopause Support Market Outlook, By Bone Health and Osteoporosis (2023–2034) (\$MN)

Table 33 Global Menopause Support Market Outlook, By Metabolic and Cardiovascular Concerns (2023–2034) (\$MN)

Table 34 Global Menopause Support Market Outlook, By Sexual Health and Libido (2023–2034) (\$MN)

Table 35 Global Menopause Support Market Outlook, By Other Symptoms (2023–2034) (\$MN)

Table 36 Global Menopause Support Market Outlook, By Route of Administration (2023–2034) (\$MN)

Table 37 Global Menopause Support Market Outlook, By Oral (2023–2034) (\$MN)

Table 38 Global Menopause Support Market Outlook, By Topical and Transdermal (2023–2034) (\$MN)

Table 39 Global Menopause Support Market Outlook, By Injectable (2023–2034) (\$MN)

Table 40 Global Menopause Support Market Outlook, By Vaginal Delivery Systems (2023–2034) (\$MN)

Table 41 Global Menopause Support Market Outlook, By Dosage Form (2023–2034) (\$MN)

Table 42 Global Menopause Support Market Outlook, By Tablets and Capsules (2023–2034) (\$MN)

Table 43 Global Menopause Support Market Outlook, By Softgels (2023–2034) (\$MN)

Table 44 Global Menopause Support Market Outlook, By Powders (2023–2034) (\$MN)

Table 45 Global Menopause Support Market Outlook, By Liquids and Tonics (2023–2034) (\$MN)

Table 46 Global Menopause Support Market Outlook, By Patches (2023–2034) (\$MN)

Table 47 Global Menopause Support Market Outlook, By Creams and Gels (2023–2034) (\$MN)

Table 48 Global Menopause Support Market Outlook, By Rings and Implants (2023–2034) (\$MN)

Table 49 Global Menopause Support Market Outlook, By End User (2023–2034) (\$MN)

Table 50 Global Menopause Support Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 51 Global Menopause Support Market Outlook, By Specialty Clinics (2023–2034) (\$MN)

Table 52 Global Menopause Support Market Outlook, By Diagnostic Centers (2023–2034) (\$MN)

Table 53 Global Menopause Support Market Outlook, By Homecare Settings (2023–2034) (\$MN)

Table 54 Global Menopause Support Market Outlook, By Wellness Centers and Gynecology Clinics (2023–2034) (\$MN)

Table 55 Global Menopause Support Market Outlook, By Distribution Channel (2023–2034) (\$MN)

Table 56 Global Menopause Support Market Outlook, By Hospitals and Clinics (2023–2034) (\$MN)

Table 57 Global Menopause Support Market Outlook, By Retail Pharmacies and Drug Stores (2023–2034) (\$MN)

Table 58 Global Menopause Support Market Outlook, By Online Pharmacies and E-commerce (2023–2034) (\$MN)

Table 59 Global Menopause Support Market Outlook, By Specialty Stores (2023–2034) (\$MN)

Table 60 Global Menopause Support Market Outlook, By Direct-to-Consumer Platforms (2023–2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.

I would like to order

Product name: Menopause Support Market Forecasts to 2034 – Global Analysis By Support Type (Hormonal Therapies, Non-Hormonal Therapies, Dietary Supplements, Lifestyle and Wellness Solutions, and Medical Devices and Digital Therapeutics), Symptom Type, Route of Administration, Dosage Form, End User, Distribution Channel, and By Geography

Product link: <https://marketpublishers.com/r/M96E06DC677CEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M96E06DC677CEN.html>